Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
TGI-2 / TG ImmunoPharma
NCT05746897: A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors	Recruiting	1	38	US	NM1F Injection, Pembrolizumab injection	Hefei TG ImmunoPharma Co., Ltd.	Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer	09/27	09/27